Bluejay Diagnostics (BJDX) Cash from Financing Activities (2020 - 2026)
Bluejay Diagnostics (BJDX) posted Cash from Financing Activities of $124096.0 for Q1 2026, down 96.66% sequentially from $3.7 million in Q4 2025, and up 12698.58% YoY from N/an in Q1 2025.
Bluejay Diagnostics (BJDX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Bluejay Diagnostics has reported Cash from Financing Activities for 6 years, with the latest figure at $124096.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 12698.58% year-over-year to $124096.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 2.92% YoY) and the FY2025 annual result came in at $7.1 million, down 30.63% from the prior year.
- Cash from Financing Activities declined to $124096.0 in Q1 2026 per BJDX's latest filing, from $3.7 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $7.6 million in Q2 2024 and troughed at -$147861.0 in Q3 2024.
- A 4-year average of $1.4 million and a median of -$985.0 in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 283122.25% in 2024, down 112.57% in 2024.
- Over 4 years, Cash from Financing Activities stood at -$3050.0 in 2023, then jumped by 56.52% to -$1326.0 in 2024, then soared by 279980.24% to $3.7 million in 2025, then plunged by 96.66% to $124096.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $124096.0, $3.7 million, and -$1015.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Bluejay Diagnostics | 1.89 Mn | 1.89 Mn | - | 7.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.56 Mn |
| Jun 30, 2026 | 7.56 Mn |
| Mar 31, 2026 | 124,096.00 |
| Mar 31, 2026 | 124,096.00 |
| Dec 31, 2025 | 3.71 Mn |
| Dec 31, 2025 | 3.71 Mn |
| Sep 30, 2025 | -1,015.00 |
| Sep 30, 2025 | -1,015.00 |
| Jun 30, 2025 | 3.38 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Mar 31, 2025 | -985.00 |
| Mar 31, 2025 | -985.00 |
| Dec 31, 2024 | -1,326.00 |
| Dec 31, 2024 | -1,326.00 |
| Sep 30, 2024 | -147,861.00 |
| Sep 30, 2024 | -147,861.00 |
| Jun 30, 2024 | 7.58 Mn |
| Jun 30, 2024 | 7.58 Mn |
| Mar 31, 2024 | 2.79 Mn |
| Mar 31, 2024 | 2.79 Mn |